Former Genzyme Corporation Subsidiary rEVO Biologics Files For $75 Million IPO
Published: Jul 01, 2014
rEVO Biologics, which markets a recombinant protein that prevents blood clots in patients with a rare disorder, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The company was originally formed as a subsidiary of Genzyme and completed an IPO in 2002, before it was bought by French pharmaceutical company LFB Biotechnologies in 2010.
Help employers find you! Check out all the jobs and post your resume.